Flexion Therapeutics Inc (FLXN) Given Average Rating of “Buy” by Brokerages
Shares of Flexion Therapeutics Inc (NASDAQ:FLXN) have earned an average rating of “Buy” from the ten brokerages that are currently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $106.25.
A number of equities analysts recently commented on FLXN shares. Janney Montgomery Scott lifted their price objective on Flexion Therapeutics to $570.00 and gave the stock a “fair value” rating in a research note on Tuesday, October 10th. Wells Fargo & Co set a $39.00 price objective on Flexion Therapeutics and gave the stock a “buy” rating in a research note on Friday, October 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Flexion Therapeutics in a research note on Sunday, September 17th. Zacks Investment Research lowered Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Finally, Royal Bank of Canada set a $44.00 price target on Flexion Therapeutics and gave the company a “buy” rating in a research note on Sunday, October 29th.
In other Flexion Therapeutics news, insider Neil Bodick purchased 2,700 shares of the company’s stock in a transaction on Tuesday, November 21st. The shares were purchased at an average cost of $24.49 per share, with a total value of $66,123.00. Following the completion of the purchase, the insider now owns 64,605 shares in the company, valued at $1,582,176.45. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Michael D. Clayman purchased 5,000 shares of the company’s stock in a transaction on Wednesday, November 8th. The stock was acquired at an average cost of $23.60 per share, for a total transaction of $118,000.00. Following the completion of the purchase, the insider now owns 35,395 shares of the company’s stock, valued at approximately $835,322. The disclosure for this purchase can be found here. 15.98% of the stock is currently owned by insiders.
Flexion Therapeutics (NASDAQ:FLXN) traded up $0.47 during trading on Friday, hitting $26.45. The company had a trading volume of 653,879 shares, compared to its average volume of 956,921. The company has a debt-to-equity ratio of 0.87, a quick ratio of 12.93 and a current ratio of 12.93. The firm has a market capitalization of $992.95, a price-to-earnings ratio of -7.51 and a beta of 1.14. Flexion Therapeutics has a one year low of $16.51 and a one year high of $32.25.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.